Veradermics (MANE) investor relations material

Executive summary

• Clinical-stage, pre-revenue business developing VDPHL01, an extended-release oral minoxidil candidate for pattern hair loss; operating losses expected as development and launch preparation continue.

• Positive Phase 3 results in men and positive Phase 2 results in women advanced VDPHL01; Study 306 topline results are expected in H1 2027.

• Cash, cash equivalents and marketable securities totaled $798.4M at September 30, 2026, with operations expected to be funded into 2030 under current plans.

Financial highlights

• Q3 R&D expense was $16.1M vs. $18.1M YoY; lower clinical and development costs were partly offset by higher payroll and stock-based compensation.

• Q3 G&A was $12.7M vs. $2.3M YoY, reflecting higher personnel and stock-based compensation, commercial readiness costs and professional fees; total operating expenses were $28.8M vs. $20.3M.

• Q3 net loss was $21.0M vs. $20.1M YoY; other income rose to $7.8M from $0.2M, primarily on higher cash and investment balances.

• 9M 2026 net loss was $71.7M vs. $48.1M; operating expenses were $88.2M vs. $49.3M, partly offset by $16.5M in other income vs. $1.2M.

• No product revenue; accumulated deficit was $195.2M at September 30, 2026.

Outlook and guidance

• Study 306 enrollment is complete, with topline data in female pattern hair loss expected in H1 2027.

• Existing cash, cash equivalents and marketable securities are expected to fund operations into 2030, including multiple Phase 3 readouts and potential launch preparations; estimates depend on assumptions and capital may be exhausted sooner.

• Significant operating losses and rising expenses are expected as VDPHL01 advances through Phase 3, regulatory review and potential commercialization; timing and costs remain difficult to predict.

• A potential application could initially target males with a later female supplement, or seek approval in both populations together.